type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Japan society for Patient Reported Outcome
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who start treatment with liraglutide (those determined to undergo treatment with liraglutide) within the limits of coverage by health insurance) and have received pretreatment with: (1) Only diet and exercise therapies (2) In addition to diet and exercise therapies, sulfonylurea agents 2) Male and female patients aged 15 years or older 3) Patients who have agreed to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Patients not prescribed liraglutide in accordance with the recommendations by the "Committee on the proper use of incretins (GLP-1 receptor agonists and DPP-4 inhibitors)" 2) Patients with previous or current treatment with insulin formulations 3) Patients receiving previous treatment with GLP-1 receptor agonists 4) Patients with hypersensitivity to this drug or excipient 5) Female patients being pregnant/breast-feeding or desiring to become pregnant within the next 12 months 6) Patients with malignancies 7) Patients meeting the contraindications for GLP-1 receptor agonist (18 mg Victoza; subcutaneous injection) (liraglutide) 8) Patients with severe complications resulting from diabetes or other causes 9) Other patients determined ineligible by an investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Variation in QOL scores based on DTR-QOL 2. Correlation of the changes in HbAlc with those of DTR-QOL scores | — |
Countries
Japan
Outcome results
None listed